Recombinant Shiga toxin B subunit elicits protection against Shiga toxin via mixed Th type immune response in mice

Gupta, Pallavi; Singh, Manglesh Kumar; Singh, Yamini; Gautam, Vandana; Kumar, Subodh; Kumar, Om; Dhaked, Ram Kumar

doi:10.1016/j.vaccine.2011.08.040

Cited by 14 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since Shiga toxin, either in E. coli or Shigella is the main virulence factor leading to the most undesirable consequences of E. coli infections, Stx has been proposed as a target for vaccination. Antigenicity is conferred by the B-subunit of the toxin and efforts have been devoted towards it (Marcato et al, 2005;Gupta et al, 2011).…”

Section: Vaccinesmentioning

confidence: 99%

Pathogenic members of Escherichia coli & Shigella spp. Shigellosis

García-Aljaro¹,

Momba²,

Muniesa³

2019

Water and Sanitation for the 21st Century: Health and Microbiological Aspects of Excreta and Wastewater Management (Global Wate

View full text Add to dashboard Cite

Section: Vaccinesmentioning

confidence: 99%

Pathogenic members of Escherichia coli & Shigella spp. Shigellosis

García-Aljaro¹,

Momba²,

Muniesa³

2019

Water and Sanitation for the 21st Century: Health and Microbiological Aspects of Excreta and Wastewater Management (Global Wate

View full text Add to dashboard Cite

“…Moreover, substantial animal data indicate that vaccination with CTB or LTB subunits is safe and effective for the prevention of CT- or LT-associated diarrhea [7, 10]. The B subunits of Stx1 and Stx2 have also been reported to be immunogenic and proposed as candidate vaccine antigens [6, 14, 15]. In addition, the B subunit-encoding gene is much smaller than the holotoxin gene, which will be advantageous for producing of recombinant proteins by gene transduction into plant cells [16].…”

mentioning

confidence: 99%

Evaluation of Recombinant Forms of the Shiga Toxin Variant Stx2eB Subunit and Non-Toxic Mutant Stx2e as Vaccine Candidates against Porcine Edema Disease

Sato

Matsui

Takita

et al. 2013

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

Porcine edema disease (ED) is a communicable disease of shoats caused by infection with Shiga toxin (Stx)-producing Escherichia coli. Stx2e is classified as a 1A5B-type toxin and is a decisive virulence determinant of ED. The single A subunit of Stx2e possesses enzymatic activity and is accompanied by a pentamer of B subunits, which binds to the host receptor and delivers the A subunit into the cell. In the present study, we used a mouse model to evaluate the immunogenicity of 3 ED vaccine candidates: a non-toxic mutant holotoxin mStx2e and 2 Stx2eB-based fusion proteins, Stx2eA2B-His and Stx2eB-His. Systemic inoculation of mice with mStx2e- and the Stx2eB-derived antigens induced anti-Stx2e IgG responses that were fully and partially capable of neutralizing Stx2e cellular cytotoxicity, respectively. Intranasal immunization with mStx2e protected the mice from subsequent intraperitoneal challenge with a lethal dose of Stx2e, whereas immunization with Stx2eA2B-His and Stx2eB-His afforded partial protection. Analysis of serum cytokines revealed that mStx2e, but not the Stx2eB-based antigens, was capable of inducing a Th2-type immune response. These results suggest that although the Stx2eB-based antigens elicited an immune response to Stx2e, they did so through a different mechanism to the Th2-type response induced by mStx2e.

show abstract

“…Various vaccine approaches have also been attempted including the development of preparations that contain bacterial peptides and virulence factors (Wen et al, 2006 ; Tiels et al, 2008 ; Gu et al, 2009 ; McNeilly et al, 2010 ; Asper et al, 2011 ; Cai et al, 2011 ; Gupta et al, 2011 ; Wan et al, 2011 ; Zhang et al, 2012 ; Rossi et al, 2013 ; Sato et al, 2013 ; Cernicchiaro et al, 2014 ; Garcia-Angulo et al, 2014 ; Lu et al, 2014 ; Mejias et al, 2014 ; Paddock et al, 2014 ), attenuated bacterial cells (Rojas et al, 2010 ; Gu et al, 2011 ; Fujii et al, 2012 ), bacterial envelope/membrane derivatives (Cai et al, 2010 ; Choi et al, 2014 ) in addition to DNA vaccines (Bentancor et al, 2009 ; Ren et al, 2013 ). These vaccine preparations have been assessed in animal models with some showing promising results (reviewed in Garcia-Angulo et al, 2013 ).…”

Section: Probiotics Phages and Vaccinesmentioning

confidence: 99%

Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype

Rahal

Fadlallah

Nassar

et al. 2015

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Shiga toxin-producing Escherichia coli (STEC) are a group of diarrheagenic bacteria associated with foodborne outbreaks. Infection with these agents may result in grave sequelae that include fatality. A large number of STEC serotypes has been identified to date. E. coli serotype O104:H4 is an emerging pathogen responsible for a 2011 outbreak in Europe that resulted in over 4000 infections and 50 deaths. STEC pathogenicity is highly reliant on the production of one or more Shiga toxins that can inhibit protein synthesis in host cells resulting in a cytotoxicity that may affect various organ systems. Antimicrobials are usually avoided in the treatment of STEC infections since they are believed to induce bacterial cell lysis and the release of stored toxins. Some antimicrobials have also been reported to enhance toxin synthesis and production from these organisms. Various groups have attempted alternative treatment approaches including the administration of toxin-directed antibodies, toxin-adsorbing polymers, probiotic agents and natural remedies. The utility of antibiotics in treating STEC infections has also been reconsidered in recent years with certain modalities showing promise.

show abstract

Recombinant Shiga toxin B subunit elicits protection against Shiga toxin via mixed Th type immune response in mice

Cited by 14 publications

References 38 publications

Pathogenic members of Escherichia coli & Shigella spp. Shigellosis

Pathogenic members of Escherichia coli & Shigella spp. Shigellosis

Evaluation of Recombinant Forms of the Shiga Toxin Variant Stx2eB Subunit and Non-Toxic Mutant Stx2e as Vaccine Candidates against Porcine Edema Disease

Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype

Contact Info

Product

Resources

About